Psychedelic Policy Push Continues: Over 60 Bills Introduced Across 22 States Post published:February 27, 2025 Post category:Analysis/News/Pα+
January 2025 Psychedelic Patent Update: Lykos’ New Continuation Applications; Ambio Files on Ibogaine & Magnesium Post published:February 25, 2025 Post category:Psychedelic Patent Analysis/Pα+
A Crucible of Academia, Psychedelics, and Religion: Psychedelic Intersections 2025 at The Harvard Divinity School Post published:February 24, 2025 Post category:News
UK Psychedelic Research Hindered by Red Tape, Experts Tell Lawmakers in Parliamentary Report Post published:February 21, 2025 Post category:Analysis/News
MDMA for Active-Duty Troops: Aaron Wolfgang on DoD’s Unprecedented Study Post published:February 19, 2025 Post category:Interviews/Pα+
Opinions: PrEP’s Rollout Offers a Roadmap for Prescription Psychedelics Post published:February 18, 2025 Post category:Opinions
Magic Mushrooms Meet Corporate Conspiracy: Steve Hely on Adult Swim’s Common Side Effects Post published:February 17, 2025 Post category:Interviews
Pα+ Psychedelic Bulletin #188: Q4’24 Lobbying Update; Virginia Lawmakers Question Purpose, Precedent of Compass Bill; VA Loses Psychedelics Champion; GH Discusses Lack of Placebo Effect Post published:February 14, 2025 Post category:Psychedelic Bulletin/Pα+
Psychedelic Funding, Public Markets, and M&A in 2024 Post published:February 12, 2025 Post category:2024 Year in Review/Analysis
Ketamine on the Edge: Mindbloom’s At-Home Injections Spark Debate; UK Eyes Tougher Laws; DEA to Regulate Telehealth Prescribing; Spravato Sales Top $1bn Post published:February 10, 2025 Post category:Analysis/News/Pα+